No Data
Tourmaline Bio: Strong Financial Position and Promising Phase II Study Results Drive Buy Rating
Tourmaline Bio Shares Are Trading Lower. The Company Reported Q1 Financial Results.
Talaris Therapeutics GAAP EPS of -$0.89
Tourmaline Bio | 10-Q: Q1 2025 Earnings Report
Tourmaline Bio | 8-K: Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
Tourmaline Bio, Inc. Confirms Progress in Phase 2 TRANQUILITY Trial and Financial Position Ahead of Key Data Readout